Interventional Oncology Global Market - Forecast To 2029

Abstract
Interventional Oncology (IO) is a rapidly growing field in cancer care that uses minimally invasive procedures performed under image guidance to diagnose and treat patients with liver, kidney, lung, Brain & Spine, prostate, and other cancers. Rather than removing tumors through open surgical procedures, these image-guided procedures can be performed in place of or in combination with other cancer treatments to provide truly comprehensive care. The advantage of these methods is that IO has much less effect on the body compared to conventional procedures.

According to IQ4I analysis, the interventional oncology global market is expected to grow at a high single from 2022 to 2029. Some of the factors driving the market are the increasing prevalence of cancer cases, the increasing geriatric population and the growing adoption of minimally invasive procedures. Factors such as technological advancements in the field of interventional oncology and expansion in emerging markets are opportunities for the market. Similarly, side effects and risks associated with the use, lack of awareness, and lack of trained professionals are restraining the market growth, While, the availability of alternative treatments and stringent regulatory guidelines are a threat to market growth.

The interventional oncology market is segmented based on products, applications, end-users, and geography. The interventional oncology market based on products is segmented as ablation and embolization. The embolization segment is expected to grow at a mid-single from 2022 to 2029. The ablation segment is the fastest-growing double digit from 2022 to 2029.

Ablation global market based on product type is sub-segmented into radiofrequency ablation, microwave ablation, Cryoablation, HIFU, and others (irreversible electroporation and MRI-guided laser ablation). Among these, microwave ablation is expected to grow at a double-digit from 2022 to 2029. The HIFU segment is the fastest-growing in high teens from 2022. Embolization global market based on procedure is sub-segmented into trans-arterial radioembolization (TARE)/selective internal radiation therapy (SIRT), trans-arterial chemo-embolization (TACE), drug-eluting beads trans-arterial chemo-embolization (DEB-TACE) and trans-arterial embolization (TAE)/bland embolization. Among procedures, TARE/SIRT is expected to grow at a mid-single from 2022 to 2029. The Bland/TAE is the fastest-growing at mid-single from 2022 to 2029.

Interventional oncology global market based on application is segmented into liver cancer, kidney cancer, lung cancer, brain & spine cancer, prostate cancer, and others. Among these applications, the liver cancer segment is expected to grow at mid-single from 2022 to 2029. Brain & spine cancer is the fastest-growing at double-digit from 2022. Further, the application market is sub-segmented into ablation and embolization applications.

The ablation market is segmented into liver cancer, kidney cancer, lung cancer, brain & spine cancer, prostate cancer, and others. Among these applications, the liver cancer segment is expected to grow double-digit from 2022 to 2029. Brain & spine cancer is the fastest-growing segment with a double-digit from 2022 to 2029.

Embolization global market based on application is segmented into liver cancer, lung cancer, prostate cancer, and others. Among embolization applications, the liver cancer segment is expected to grow at mid-single from 2022 to 2029.

The interventional Oncology global market by end-users is segmented into hospitals, ambulatory surgical centers (ASC), and academics & research institutes. Among end-users, the hospital is expected to grow at a high single from 2022 to 2029. The ambulatory surgical center is the fastest-growing at a high single from 2022 to 2029.

The interventional oncology market by region is segmented as North America (U.S. and Rest of North America), Europe (Germany, France, Italy, and Rest of Europe), Asia-Pacific (China, Japan, Australia, and Rest of APAC), and the Rest of the world (Brazil, Rest of LATAM and the Middle East & Others). North America is expected to be at a high single from 2022 to 2029. Mainly due to increasing incidences of cancer, increasing demand for minimally invasive surgeries, favorable reimbursements, product launches, and availability of skilled personnel. The Asia-Pacific is the fastest-growing region with a double-digit from 2022 to 2020. Due to the increasing geriatric population and increasing incidence of cancer, increased expenditure on healthcare facilities, increasing awareness about interventional oncology, and low-cost surgery is driving the market.

The interventional oncology global market is a consolidated market with the top 6 players occupying a major share of the market hence all the existing players in this market are involved in developing new and advanced therapeutics to maintain their market shares. Some of the major players in the interventional oncology market include Medtronic Plc (Ireland), Sirtex Medical (China), Boston Scientific Corporation (U.S.), Angiodynamics (U.S.), Guerbet (France), Merit Medical System (U.S.), Siemens healthineers, Inc. (Varian) (Germany.), Terumo Corporation (Japan), Johnson & Johnson (U.S.), AngioDynamics, Inc. (U.S.), and Monteris Medical (U.S.).

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
North America
The U.S.
Rest of North America
Europe
Germany
France
Italy
Rest of Europe
Asia-Pacific
Japan
China
Australia
Rest of APAC
Rest of the World (RoW)
Brazil
Rest of LATAM
The Middle East and Others

Content
Table of Contents

1 EXECUTIVE SUMMARY 21
2 INTRODUCTION 27
2.1 KEY TAKEAWAYS 27
2.2 SCOPE OF THE REPORT 28
2.3 REPORT DESCRIPTION 28
2.4 MARKETS COVERED 31
2.5 STAKEHOLDERS 32
2.6 RESEARCH METHODOLOGY 33
2.6.1 MARKET SIZE ESTIMATION 35
2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION 37
2.6.3 SECONDARY SOURCES 38
2.6.4 PRIMARY SOURCES 39
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES 39
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES 40
2.6.7 ASSUMPTIONS 41
3 MARKET ANALYSIS 43
3.1 INTRODUCTION 43
3.2 MARKET SEGMENTATION 44
3.3 FACTORS INFLUENCING MARKET 47
3.3.1 DRIVERS AND OPPORTUNITIES 47
3.3.1.1 Increasing incidence of cancer cases 47
3.3.1.2 Growing adoption of minimally invasive procedures 48
3.3.1.3 Increasing geriatric population 49
3.3.1.4 Technological advancements in the field of interventional oncology 49
3.3.1.5 Expansion in the emerging markets 51
3.3.2 RESTRAINTS AND THREATS 52
3.3.2.1 Side effects and risks associated with the use 52
3.3.2.2 Lack of awareness 52
3.3.2.3 Lack of trained professionals 53
3.3.2.4 Availability of alternative treatments 54
3.3.2.5 Stringent regulatory guidelines 54
3.4 REGULATORY AFFAIRS 55
3.4.1 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION 56
3.4.1.1 ISO 9001: 2015 Quality Management System 56
3.4.1.2 ISO:13485 Medical Devices 56
3.4.1.3 ISO 10993 Biological Evaluation Of Medical Devices 57
3.4.1.4 ISO 14971 Risk Management Of Medical Devices 57
3.4.1.5 ISO 12807:2018 Safe Transport of Radioactive Materials- Leakage Testing on Packages 57
3.4.1.6 IEC 60601-1 Medical Electrical Equipment Standard 58
3.4.1.7 IEC 60601-1-2 Electromagnetic Compatibility (EMC) for Medical Devices 58
3.4.2 U.S. 58
3.4.3 CANADA 60
3.4.4 EUROPE 60
3.4.5 JAPAN 61
3.4.6 CHINA 62
3.4.7 INDIA 64
3.5 CLINICAL TRIALS DATA 66
3.6 PORTER’S FIVE FORCE ANALYSIS 70
3.6.1 THREAT OF NEW ENTRANTS 71
3.6.2 THREAT OF SUBSTITUTES 72
3.6.3 BARGAINING POWER OF SUPPLIERS 72
3.6.4 BARGAINING POWER OF BUYERS 73
3.6.5 COMPETITIVE RIVALRY 73
3.7 SUPPLY CHAIN ANALYSIS 74
3.8 FUNDING SCENARIO 78
3.9 MARKET SHARE ANALYSIS BY MAJOR PLAYERS 80
3.9.1 INTERVENTIONAL ONCOLOGY GLOBAL MARKET SHARE ANALYSIS 80
3.9.2 IO ABLATION GLOBAL MARKET SHARE ANALYSIS 83
3.9.3 IO EMBOLIZATION GLOBAL MARKET SHARE ANALYSIS 85
3.9.4 RADIOFREQUENCY ABLATION GLOBAL MARKET SHARE ANALYSIS 88
3.9.5 IO MICROWAVE ABLATION GLOBAL MARKET SHARE ANALYSIS 90
3.9.6 IO TARE GLOBAL MARKET SHARE ANALYSIS 92
3.9.7 IO DEB-TACE GLOBAL MARKET SHARE ANALYSIS 94
3.9.8 IO TAE GLOBAL MARKET SHARE ANALYSIS 96
3.10 INTERVENTIONAL ONCOLOGY PROCEDURE VOLUME,
BASED ON PRODUCT TYPE 97
3.10.1 IO ABLATION DEVICES UNITS PER PROCEDURE, AVERAGE SELLING PRICE, NUMBER OF PROCEDURES AND UNITS SOLD 101
3.10.2 IO EMBOLIZATION UNITS PER PROCEDURE, AVERAGE SELLING PRICE
AND NUMBER OF PROCEDURES 103
3.11 INTERVENTIONAL ONCOLOGY NUMBER OF UNITS BASED ON REGION 105
3.11.1 IO ABLATION DEVICES NUMBER OF UNITS BASED ON REGION 105
3.11.2 IO RADIOFREQUENCY ABLATION DEVICES NUMBER OF UNITS,
BASED ON REGION 108
3.11.3 IO MICROWAVE ABLATION DEVICES NUMBER OF UNITS,
BASED ON REGION 110
3.11.4 IO CRYOABLATION DEVICES NUMBER OF UNITS BASED ON REGION 112
3.11.5 ANALYSIS OF INTERVENTION ONCOLOGY ABLATION DEVICES BY UNIT VOLUME BASED ON COUNTRY (NOS) 114
4 INTERVENTIONAL ONCOLOGY GLOBAL MARKET, BASED ON PRODUCT 115
4.1 INTRODUCTION 115
4.2 ABLATION 117
4.2.1 RADIOFREQUENCY ABLATION 121
4.2.2 MICROWAVE ABLATION 124
4.2.3 CRYOABLATION 126
4.2.4 HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU) 129
4.2.5 OTHER ABLATION 131
4.3 EMBOLIZATION 133
4.3.1 IO TRANS-ARTERIAL RADIO-EMBOLIZATION(TARE)/
SELECTIVE INTERNAL RADIATION THERAPY (SIRT) 136
4.3.2 IO TRANSARTERIAL CHEMO-EMBOLIZATION (TACE) 138
4.3.3 IO DRUG-ELUTING BEADS TRANSARTERIAL CHEMO-EMBOLIZATION
(DEB-TACE) 140
4.3.4 IO BLAND EMBOLIZATION/ TRANSARTERIAL EMBOLIZATION (TAE) 142
5 INTERVENTIONAL ONCOLOGY GLOBAL MARKET,
BASED ON APPLICATION 147
5.1 INTRODUCTION 147
5.1.1 LIVER CANCER 153
5.1.2 KIDNEY CANCER 157
5.1.3 LUNG CANCER 159
5.1.4 BRAIN AND SPINE CANCER 163
5.1.5 PROSTATE CANCER 165
5.1.6 OTHER APPLICATIONS 169
6 INTERVENTIONAL ONCOLOGY GLOBAL MARKET, BASED ON END-USERS 174
6.1 INTRODUCTION 174
6.1.1 HOSPITALS 177
6.1.2 AMBULATORY SURGICAL CENTERS (ASCS) 180
6.1.3 ACADEMICS AND RESEARCH INSTITUTES 182
7 REGIONAL ANALYSIS 184
7.1 INTRODUCTION 184
7.2 NORTH AMERICA 188
7.2.1 U.S. 205
7.2.2 REST OF NORTH AMERICA 211
7.3 EUROPE 217
7.3.1 GERMANY 234
7.3.2 FRANCE 240
7.3.3 ITALY 245
7.3.4 REST OF E.U. 250
7.4 APAC 255
7.4.1 CHINA 272
7.4.2 JAPAN 278
7.4.3 AUSTRALIA 283
7.4.4 REST OF APAC 288
7.5 ROW 293
7.5.1 BRAZIL 310
7.5.2 REST OF LATAM 316
7.5.3 MIDDLE EAST AND OTHERS 321
8 MAJOR COMPANIES 326
8.1 ANGIODYNAMICS INC. 326
8.1.1 OVERVIEW 326
8.1.2 FINANCIALS 327
8.1.3 PRODUCT PORTFOLIO 329
8.1.4 KEY DEVELOPMENTS 330
8.1.5 BUSINESS STRATEGY 330
8.1.6 SWOT ANALYSIS 331
8.2 BOSTON SCIENTIFIC CORPORATION 332
8.2.1 OVERVIEW 332
8.2.2 FINANCIALS 333
8.2.3 PRODUCT PORTFOLIO 336
8.2.4 KEY DEVELOPMENTS 336
8.2.5 BUSINESS STRATEGY 336
8.2.6 SWOT ANALYSIS 337
8.3 CDH INVESTMENTS (CDH GENTECH LTD), (SIRTEX LTD.) 338
8.3.1 OVERVIEW 338
8.3.2 FINANCIALS 338
8.3.3 PRODUCT PORTFOLIO 339
8.3.4 KEY DEVELOPMENTS 339
8.3.5 BUSINESS STRATEGY 339
8.3.6 SWOT ANALYSIS 340
8.4 GUERBET 341
8.4.1 OVERVIEW 341
8.4.2 FINANCIALS 342
8.4.3 PRODUCT PORTFOLIO 344
8.4.4 KEY DEVELOPMENTS 344
8.4.5 BUSINESS STRATEGY 345
8.4.6 SWOT ANALYSIS 345
8.5 JOHNSON & JOHNSON 346
8.5.1 OVERVIEW 346
8.5.2 FINANCIALS 347
8.5.3 PRODUCT PORTFOLIO 349
8.5.4 KEY DEVELOPMENTS 349
8.5.5 BUSINESS STRATEGY 349
8.5.6 SWOT ANALYSIS 350
8.6 MEDTRONIC, PLC 351
8.6.1 OVERVIEW 351
8.6.2 FINANCIALS 352
8.6.3 PRODUCT PORTFOLIO 356
8.6.4 KEY DEVELOPMENTS 356
8.6.5 BUSINESS STRATEGY 357
8.6.6 SWOT ANALYSIS 357
8.7 MERIT MEDICAL SYSTEMS, INC 358
8.7.1 OVERVIEW 358
8.7.2 FINANCIALS 359
8.7.3 PRODUCT PORTFOLIO 362
8.7.4 KEY DEVELOPMENTS 363
8.7.5 BUSINESS STRATEGY 363
8.7.6 SWOT ANALYSIS 364
8.8 MONTERIS MEDICAL 365
8.8.1 OVERVIEW 365
8.8.2 FINANCIALS 365
8.8.3 PRODUCT PORTFOLIO 365
8.8.4 KEY DEVELOPMENTS 366
8.8.5 BUSINESS STRATEGY 366
8.8.6 SWOT ANALYSIS 367
8.9 SIEMENS HEALTHINEERS (VARIAN MEDICAL) 368
8.9.1 OVERVIEW 368
8.9.2 FINANCIALS 369
8.9.3 PRODUCT PORTFOLIO 370
8.9.4 KEY DEVELOPMENTS 371
8.9.5 BUSINESS STRATEGY 371
8.9.6 SWOT ANALYSIS 372
8.10 TERUMO CORPORATION 373
8.10.1 OVERVIEW 373
8.10.2 FINANCIALS 374
8.10.3 PRODUCT PORTFOLIO 375
8.10.4 KEY DEVELOPMENTS 376
8.10.5 BUSINESS STRATEGY 376
8.10.6 SWOT ANALYSIS 377